Akari Therapeutics Secures $5.5M Private Placement at Deep Discount, Facing Extreme Dilution
AKTX has more than doubled off its 52-week low of $3.015 on elevated volume (50× avg).
Summary
Akari Therapeutics announced a $5.5 million private placement of ADSs and warrants at a deep discount to market price, providing crucial capital but causing extreme dilution.
Key Events · Financing and Capital Events · AKTX
-
Secures $5.5 Million Capital
The company entered into a securities purchase agreement for a private placement expected to generate approximately $5.5 million in gross proceeds. This finalizes the terms and pricing of the offering initiated with the S-1 filing on 2026-05-08.
-
Deep Discount Pricing
Units (ADSs or prefunded warrants plus three series of warrants) are priced at $3.74, a substantial discount to the current stock price of $15.16.
-
Extreme Dilution Potential
The offering involves 1,470,588 ADSs (or prefunded warrants) and three series of warrants (Series H, I, J), each exercisable for one ADS, representing significant potential future dilution. An additional 117,647 ADSs will be issued to the placement agent.
-
Addresses Going Concern Warning
This capital raise is critical for the company, which recently reported a "going concern" warning in its 2026-05-19 10-Q filing and a cash runway extending only into June 2026.
Analysis · AKTX · Life Sciences
Akari Therapeutics has finalized a critical $5.5 million private placement offering, which is essential for the company's immediate survival given its recent "going concern" warning and limited cash runway. However, the terms are highly dilutive for existing shareholders. The offering is priced at a significant discount to the current market price, and includes multiple series of warrants that could lead to substantial additional dilution upon exercise.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTX was trading at $15.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $3.02 to $56.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.